Travere Therapeutics (TVTX) delivered a quarterly update that caught investors’ attention, as the company posted substantial revenue growth and turned a profit in Q3 2025. The results reflected strong ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the best-performing stocks on Friday. Travere Therapeutics climbed to a ...

Discover key Q3 2025 earnings insights for Travere Therapeutics, including FILSPARI sales growth, FDA milestones, and outlook for rare kidney ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ:TVTX) reported third-quarter earnings that significantly exceeded analyst expectations, driven by robust sales growth of its kidney disease ...

Travere Therapeutics stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug, ...

Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics, Inc.

Travere Therapeutics (TVTX) is scheduled to announce Q3 earnings results on Thursday, October 30th, after market close. The consensus EPS Estimate is -$0.09 (+8 ...

Shares of Travere Therapeutics rose after the company beat analysts' expectations in swinging to a third-quarter profit. The stock rose 14% to $33.67, and at one point touched a new 52-week high of ...

Inc. (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast ...

Vicarious Surgical Inc. ("Vicarious Surgical" or the "Company") , a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report ...

As of Oct. 31, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as ...